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Abstract
Introduction: Anaemia is one of the arms of the cardio-renal-anaemia syndrome
(CRA) in chronic kidney disease (CKD) patients. The correction of anaemia was
effective in the amelioration of both cardiac and renal failure. We studied the
relationship between the severity of CRA syndrome in peritoneally dialyzed
patients and their survival probability. 
Material and methods: Fifty-six patients on peritoneal dialysis were followed for
1 year. Definition of the severity of the CRA in dialysis patients: cardiac arm – NYHA
class I-IV = 1-4 points, renal arm – non-diabetic patients age < 65 = 1 point, non-
diabetic patients age > 65 = 2 points, diabetic patients age < 65 = 3 points,
diabetic patients age > 65 = 4 points, anaemia arm – Hb 11-13 g/dl (male), 
11-12 g/dl (female) = 1 point, Hb 10-11 g/dl = 2 points, Hb 9-10 g/dl = 3 points,
Hb < 9 g/dl = 4 points. The severity score = cardiac + renal + anaemia arms score
divided by 3 (maximum 4 points). 
Results: A total of 10/56 patients (18%) died during the study. The median value
for the severity score of the whole group was 1.69. In Kaplan-Meier analysis CRA
severity score was strongly associated with mortality (p < 0.001). It also correlated
with albumin, CRP, erythropoietin treatment, Hb and fasting glucose. In the
multivariate regression analysis age, Hb, albumin, and presence of diabetes
remained significant predictors of death.
Conclusions: The severity score of CRA syndrome in peritoneally dialyzed patients
is an independent and very significant predictor of death. The patients with
a high severity score had more hypoalbuminaemia, higher inflammation markers
and higher prevalence of diabetes and chronic heart failure. Cardio-renal-anaemia
syndrome severity scoring as defined by us could be an easy tool to predict
outcome of dialysis patients. 
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Introduction
Kidney disease and cardiovascular disease seem to be lethally
synergistic and both approach epidemic level, particularly in the elderly
[1]. As the population survives to an increasingly older age the number of
new cases of congestive heart failure and of end-stage kidney disease is
rising steadily. Moreover, these two entities are inexorably linked – indeed
they seem to act like Siamese twins. In addition to this combination, there
is often a third factor seen in both conditions – anaemia [2]. Cardiovascular
disease is a major contributor to mortality and morbidity in patients with
chronic renal failure [3]. As the population’s life expectancy increases, the
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incidence of both congestive heart failure (CHF) and
end-stage renal disease (ESRD) is progressively
increasing. Both diseases are inexorably linked. In
an era when cardiovascular mortality in developed
countries has been declining in the general
population, no such reduction in mortality from
cardiovascular diseases in patients with end-stage
renal disease has been noted. On the contrary,
mortality from heart disease of all causes has
progressively increased, resulting in approximately
50% of all deaths and about 30% of hospitalizations
[3]. Chronic heart failure (CHF) is present in more
than one-third of incident dialysis patients [4].
Median survival of dialyzed patients with CHF is
significantly shorter than without CHF [5]. It is
reported to be 36 months compared with 62
months for patients without CHF [5]. Moreover, less
than 15% of dialysis patients with CHF are alive 
3 years after hospitalization for CHF [6]. Anaemia
is also a common complication of chronic kidney
disease (CKD), worsening the survival of this
particularly vulnerable population [7]. On the other
hand, anaemia is frequently seen in CHF, with
a prevalence ranging from 4% to 55%, depending
on the population studied [8]. In an analysis from
the SOLVD trial, for example, 22% of the patients
had a haematocrit less than 39% and 4% had
values below 35% [9]. A similar rate of anaemia
(17%) was noted in a population-based cohort of
12,065 patients with newly diagnosed CHF [10]. The
incidence of anaemia appears to increase with
worsening functional class, from 9% for NYHA class I,
to 79% for NYHA class IV [11]. Moreover, anaemia
in CHF patients has been associated with increased
mortality and number of hospitalizations and
a greater severity of CHF, relative to non-anaemic
subjects [12]. 
Taking all these data into consideration, we
aimed to study possible relations between cardio-
renal-anaemia syndrome (CRA) in peritoneally
dialyzed patients and their survival probability. 
Material and methods
The study was performed on 56 prevalent chronic
ambulatory peritoneal dialysis (CAPD) patients
(mean age 56 ±17 years, time on dialysis 31 ±14
months). In CAPD patients renal failure was due to
glomerulonephritis (n = 17), chronic interstitial
nephritis (n = 4), polycystic kidney disease (n = 6),
diabetes (n = 18), others (lupus nephritis n = 2,
nephrolithiasis n = 1, reflux nephropathy n = 2,
hypertensive nephropathy n= 2) or unknown (n = 4).
Dialysis adequacy was assessed by measuring Kt/V
(mean Kt/V – 2.13  ±0.34). Forty-four patients were
treated with recombinant human erythropoietin
and 45 with hypotensive drugs. Twenty-one
patients were anuric, in 35 residual renal function
was present (daily urine volume ranged from 300 ml
to 2400 ml, median 1460 ml/day). In all CAPD
patients blood was drawn in the morning between
8.00 am and 9.00 am when they appeared for routine
examination at the outpatient unit after overnight
fast. Blood was taken without stasis. Samples were
aliquoted and stored at –40°C up to one month
before assay. The patients’ height and weight were
recorded for all groups. All the patients were
informed about the aim of the study and gave their
consent. The study was approved by the Medical
University Ethics Committee. All the parameters were
measured by means of standard laboratory methods.
hsCRP was assayed using commercially available kits
from American Diagnostica, New Haven, Ct, USA.
Heart failure severity was assessed using NYHA class.
Definition of the severity of CRA in dialysis patients:
cardiac arm – NYHA class I-IV = 1-4 points, renal arm
– non-diabetic patients age < 65 = 1 point, non-
diabetic patients age > 65 = 2 points, diabetic
patients age < 65 = 3 points, diabetic patients 
age > 65 = 4 points, anaemia arm – haemoglobin
(Hb) 11-13 g/dl (male), 11-12 g/dl (female) = 1 point, 
Hb 10-11 g/dl = 2 points, Hb 9-10 g/dl = 3 points, 
Hb < 9 g/dl = 4 points. The severity score = cardiac +
renal + anaemia arms score divided by 3 (maximal 
4 points). 
Data were analysed using Statistica 7.0
computer software. Normality of variable distri  -
bution was tested using Shapiro-Wilk W-test. If data
were not distributed normally, they were
logarithmically transformed to achieve normal
distribution (hsCRP). Data were reported as means
± SD. Student’s t-test or Mann-Whitney U test was
used to compare differences between groups with
p < 0.05 considered statistically significant, when
appropriate. Patient survival was estimated using
the Kaplan-Meier method and groups compared
using the log-rank test. Candidate risk factors with
a p-value < 0.1 in the univariate analysis were
considered for the multivariable model.
Results 
Basal clinical and biochemical characteristics are
presented in Table I. The median value for the
severity score of the whole group of dialysis
patients was 1.69. Patients with a median above
1.69 were significantly older, with higher NYHA class,
lower haemoglobin, higher fasting glucose and
hsCRP, and lower albumin. Diabetes was also more
prevalent in this population (60% vs. 10%, p < 0.001).
Systolic blood pressure was 140 ±23 mmHg,
whereas diastolic blood pressure was 84 ±12 mm Hg.
Only 22% of patients reached target blood pressure
of 130/80 mmHg. 
The most commonly used hypotensive drugs in
the peritoneal dialysis (PD) population were: 
β-blockers (83%), calcium channel blockers (68%),
angiotensin convertase enzyme (ACE) inhibitorsArch Med Sci 4, August / 2010 541
The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients
(66%) and diuretics (37%) with mean number of
hypotensive of 3. Only 2 patients did not require
hypotensive drugs to control blood pressure. All 
of the patients were treated with ESA, except 
7 subjects. All of them were given iron supplements,
folic acid, and phosphate binders. 
A total of 10 out of 56 patients (18%) died during
the study (9 due to cardiovascular disease). In
Kaplan-Meier analysis CRA severity score was
strongly associated with mortality (p <0.001, 
Figure 1). The severity score was also correlated
with albumin (r = –0.38, p < 0.05), C-reactive protein
(CRP) (r = 0.30, p < 0.05), erythropoietin treatment
(r = 0.33, p < 0.05), Hb (r = –0.72, p < 0.001), age 
(r =0.60, p < 0.001), NYHA class (r = 0.82, p <0.001),
presence of diabetes (r = 0.61, p < 0.001) and
fasting glucose (r = 0.30, p < 0.05). In the
multivariate regression analysis age (HR 1.91, 95% CI
1.28-2.94, p < 0.001), haemoglobin (HR 1.16, 95% CI
1.08-1.44,  p < 0.05), albumin (HR 1.19, 95% CI
0.50-0.96, p < 0.01), and presence of diabetes (HR
1.29, 95% CI 1.28-1.99, p  < 0.001), remained
significant predictors of death. If we exclude all the
components of the CRA scoring system, the only
predictor of death was albumin (HR 3.14 95% CI
0.23-0.69, p < 0.001). 
Discussion
In the present study we assessed the rela  -
tionship between the severity of CRA syndrome in
chronic peritoneally dialyzed patients and survival
probability. We found that the severity score of CRA
syndrome in peritoneally dialyzed patients was an
Parameter CRA > 1.69, n = 25 CRA < 1.69, n = 31
Age [years] 66.38 ±12.10*** 48.32 ±14.01
BMI [kg/m2] 24.9 ±4.5 24.3 ±4.9
Ht [%] 32.45 ±4.24*** 38.74 ±3.93
Hb [g/dl] 11.27 ±1.55** 12.19 ±1.11
Erythrocyte count [× 106/µl] 3.70 ±0.54* 4.16 ±0.47
Leukocyte count [× 103/µl] 7.92 ±2.52 5.98 ±1.83
MCV [fl] 91.42 ±4.45 91.28 ±6.28
Platelet count [× 103/µl] 236.33 ±79.52 214.87 ±42.54
Iron [µg/dl] 57.43 ±13.37 62.08 ±29.89
TIBC [µg/dl] 194.00 ±48.89 224.92 ±46.26
Ferritin [ng/ml]  315.09 ±249.85 250.98 ±184.61
hsCRP [mg/l]  11.80 ±9.21** 4.95 ±3.98 
Total protein [g/dl] 6.36 ±0.47 6.72 ±0.57
Albumin [g/dl] 3.39 ±0.42* 3.80 ±0.49
Glucose [mg/dl] 124.18 ±47.59* 99.07 ±36.31
Calcium [mmol/l] 2.19 ±0.25 2.14 ±0.26
Phosphate [mg/dl] 5.14 ±1.31 4.91 ±1.48
NYHA class 3.04 ±0.74 1.42 ±0.50
rHuEPO dose [IU/week] 4540 ±3335* 3083 ±2799
CRA severity score 2.46 ±0.54*** 1.17 ±0.33
Table I. Basal clinical characteristics of the studied groups
Values given are means ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 CRA > 1.69 vs. CRA < 1.69
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Figure 1. Kaplan-Meier survival curve in peritoneally
dialysed patients 
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independent and very significant predictor of death.
In addition, patients with a high severity score had
more hypoalbuminaemia and higher inflammation
markers, and certainly were more anaemic and
diabetic, with higher NYHA class. To the authors’
knowledge, this is the first report on the relationship
between anaemia, CHF severity, diabetes and
mortality in a PD population. In our population 34%
of patients were in NYHA class III or IV. The overall
prevalence of CHF in this population was 62%. In
a study of the Medicare population of the USA,
patients with either CKD or diabetes were at much
greater risk of developing atherosclerotic vascular
disease, CHF or ESRD over a 2-year period [13].
Combination of CKD and diabetes increased the
risks even further, with prevalence of CHF in this
population at 54.1% [13]. On an absolute basis,
however, the high death rates of patients with CKD
may reflect accelerated rates of atherosclerotic
vascular disease and congestive heart failure. Large
observational studies examining the association
between anaemia and “hard” clinical outcomes are
rare in patients with CKD. In another study by Li et
al. [14] using the General Medicare 5% Denominator
Files 49% of CKD patients older than 67 years were
anaemic. Anaemia was associated with age, female
gender, black race and other co-morbid conditions
including CHF, gastrointestinal bleeding, and liver
disease. Anaemic patients were more prone to
atherosclerotic vascular disease, ESRD, death, CHF
and hospitalization. In our study anaemia was
a part of CRA syndrome and subjects with a higher
CRA severity score had lower haemoglobin; also,
haemoglobin was one of the strongest predictors
of death in our population. Silverberg et al. [15] in
their review called CRA syndrome a vicious circle of
destruction. The combined presence of these three
diseases increases the risks of mortality, morbidity
and hospitalization. They are also associated with
an increase in at least four mechanisms than 
can damage the tissues: an increase in sympathetic
activity, an increase in renin-angiotensin-
aldosterone system (RAAS) activity, and an enhan  -
ce  ment of oxidative stress and inflammation [16].
In addition, more worrisome is the fact that all the
mechanisms can activate each other and destroy
the body’s cells. In our study we found that albumin,
a negative marker of inflammation, was a predictor
of death. Anaemia is more prevalent in advanced
CHF. From previous studies in CHF patients, it has
been noted that anaemia may be incidental or
directly related to CHF itself. Increased circulating
cytokines, haemodilution, iron deficiency, the use
of ACE inhibitors, renal dysfunction, poor nutrition
and decreased bone marrow perfusion may all
contribute to the development of anaemia in this
population [17-19]. However, after several trials,
including the SOLVD, ELITE II, COPERNICUS, CHARM,
VAL-HEFT and others, anaemia was recognized as
an important risk factor for mortality and morbidity
in CHF patients [20-22]. Anaemia in CHF is also
often associated with decreased renal function,
more rapid deterioration of kidney disease, and
signs of malnutrition and inflammation, such as low
body mass index (BMI), low serum albumin, low
serum total protein, low serum cholesterol,
increased CRP and deranged adrenal steroid
metabolism characteristic of catabolism, as
quantified by the cortisol [23-25]. The odds ratios
of (OR) mortality and hospitalization in patients
with anaemia are similar to those of four other
common cardiovascular risk factors: smoking,
diabetes mellitus, hypertension and hyper  -
cholesterolaemia. It is for this reason that we have
called anaemia “the fifth cardiovascular risk factor”,
after the other four risk factors [26, 27].
There are very limited reports on cardiovascular
risks factor in the PD population. In a recent study
from Latin America on 298 prevalent PD patients,
systolic heart failure was strongly associated with
diabetes and hypoalbuminaemia [28], factors we
found to be strong predictors of mortality. In
addition, anaemia was associated significantly with
left ventricular hypertrophy. To address the highly
complex interrelated nature of CKD and diabetes,
hypertension, and cardiovascular disease, Collins
et al. [29] examined CKD prevalence by the
predictive effect of demographic factors, comorbid
conditions, and CKD risk factors by using National
Health and Nutrition Examination Survey (NHANES)
1999-2004 data. They found that CKD prevalence
increased with age, and was greater in diabetes,
the greatest for diabetes and hypertension. Age and
diabetes were also strong predictors of death in our
PD population. In Japan, from among 327 ESRD
patients initiated on PD from April 1995 to March
2005 in the Kidney and Dialysis Centre, Saitama
Medical School, 8 developed de novo cardiovascular
and cerebrovascular complications. No significant
differences were observed in blood pressure, CTR,
haemoglobin, total cholesterol, triglycerides, or
HbA1c between the groups. A decrease in serum
albumin after commencement of dialysis is an
important risk factor for, and a strong predictor of,
vascular complications in patients on PD [30]. In
the multicentre cross-sectional study, performed to
evaluate the prevalence of heart failure (HF) and
the associated cardiovascular (CV) risk factors in
298 PD patients from Argentina and Uruguay, the
prevalence of CV risk factors was 73% hypertension,
51% sedentarism, 18% diabetes, 16.8% obesity, 12%
smokers, 42.3% phosphorus > 5.5 mg per 100 ml,
42.3% parathyroid hormone > 300 pg/ml, and 29.6%
calcium phosphate product > 55. Variables
associated with LVH in the multivariate analysis
were anaemia (OR = 4.06, p < 0.001) and previousArch Med Sci 4, August / 2010 543
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haemodialysis (OR = 1.99, p < 0.031). In a single
Colombian centre, using a retrospective cohort
study, survival and mortality risk factors in the
dialysis population were evaluated. For peritoneal
dialysis patients, the significant risk factors were
diabetes mellitus (p = 0.01) and albumin < 2.5 g/dl
(p = 0.02) [31].
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